Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease

Antonio Pisani, Massimo Sabbatini, Massimo Imbriaco, Eleonora Riccio, Nadia Rubis, Anna Prinster, Annalisa Perna, Raffaele Liuzzi, Letizia Spinelli, Michele Santangelo, Giuseppe Remuzzi, Piero Ruggenenti

Research output: Contribution to journalArticle

Abstract

Background & Aims: Short-term studies have shown that somatostatin analogues are effective in patients with polycystic kidney and liver disease. We evaluated the long-term effects of long-acting release octreotide (octreotide LAR), a somatostatin inhibitor, vs placebo in these patients. Methods: We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m2 or more) at a single center in Italy. We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years. The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended. Results: Baseline characteristics were similar between groups. After 3 years, TLV decreased by 130.2 ± 133.2 mL in patients given octreotide LAR (7.8% ± 7.4%) (P = .003) but increased by 144.3 ± 316.8 mL (6.1% ± 14.1%) in patients given placebo. Change vs baseline differed significantly between groups (P = .004). Two years after treatment ended, TLV had decreased 14.4 ± 138.4 mL (0.8% ± 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 ± 331.7 mL (11.0% ± 14.4%) in patients given placebo. Changes vs baseline still differed significantly between groups (P = .046). Decreases in TLV were similar in each sex; the change in TLV was greatest among subjects with larger baseline TLV. No patient withdrew because of side effects. Conclusions: In a placebo-controlled study of patients with polycystic kidney and liver disease, 3 years of treatment with octreotide LAR significantly reduced liver volume; reductions were maintained for 2 years after treatment ended. Octreotide LAR was well-tolerated. ClinicalTrials.gov number: NCT02119052.

Original languageEnglish
Pages (from-to)1022-1030
Number of pages9
JournalClinical Gastroenterology and Hepatology
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Keywords

  • ADPKD volume
  • Cyst growth
  • Somatostatin analogue

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease'. Together they form a unique fingerprint.

  • Cite this

    Pisani, A., Sabbatini, M., Imbriaco, M., Riccio, E., Rubis, N., Prinster, A., Perna, A., Liuzzi, R., Spinelli, L., Santangelo, M., Remuzzi, G., & Ruggenenti, P. (2016). Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 14(7), 1022-1030. https://doi.org/10.1016/j.cgh.2015.12.049